“Hypothesis: structures, evolution, and ancestor of glucose kinases in the hexokinase family”. Journal of Bioscience and Bioengineering99 (4): 320–30. (April 2005). doi:10.1263/jbb.99.320. PMID16233797.
“Cloning and biochemical characterization of a novel mouse ADP-dependent glucokinase”. Biochemical and Biophysical Research Communications315 (3): 652–8. (March 2004). doi:10.1016/j.bbrc.2004.01.103. PMID14975750.
“Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm”. Diabetes45 (2): 223–41. (February 1996). doi:10.2337/diabetes.45.2.223. PMID8549869.
“Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities”. Diabetes47 (3): 307–15. (March 1998). doi:10.2337/diabetes.47.3.307. PMID9519733.
“Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia”. Diabetes48 (9): 1698–705. (September 1999). doi:10.2337/diabetes.48.9.1698. PMID10480597.
“Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase”. Structure12 (3): 429–38. (March 2004). doi:10.1016/j.str.2004.02.005. PMID15016359. "Beautiful structural pictures illustrating the conformational changes and potential regulatory mechanisms"
“Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy”. Human Mutation22 (5): 353–62. (November 2003). doi:10.1002/humu.10277. PMID14517946.
“Glucokinase is an integral component of the insulin granules in glucose-responsive insulin secretory cells and does not translocate during glucose stimulation”. Diabetes53 (9): 2346–52. (September 2004). doi:10.2337/diabetes.53.9.2346. PMID15331544.
“Glucokinase activators in diabetes management”. Expert Opinion on Investigational Drugs17 (2): 145–67. (February 2008). doi:10.1517/13543784.17.2.145. PMID18230050.
“Assessing the potential of glucokinase activators in diabetes therapy”. Nature Reviews. Drug Discovery8 (5): 399–416. (May 2009). doi:10.1038/nrd2850. PMID19373249.
“A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014”. Expert Opinion on Therapeutic Patents24 (8): 875–91. (August 2014). doi:10.1517/13543776.2014.918957. PMID24821087.
“Hypothesis: structures, evolution, and ancestor of glucose kinases in the hexokinase family”. Journal of Bioscience and Bioengineering99 (4): 320–30. (April 2005). doi:10.1263/jbb.99.320. PMID16233797.
“Cloning and biochemical characterization of a novel mouse ADP-dependent glucokinase”. Biochemical and Biophysical Research Communications315 (3): 652–8. (March 2004). doi:10.1016/j.bbrc.2004.01.103. PMID14975750.
“Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm”. Diabetes45 (2): 223–41. (February 1996). doi:10.2337/diabetes.45.2.223. PMID8549869.
“Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities”. Diabetes47 (3): 307–15. (March 1998). doi:10.2337/diabetes.47.3.307. PMID9519733.
“Structural model of human glucokinase in complex with glucose and ATP: implications for the mutants that cause hypo- and hyperglycemia”. Diabetes48 (9): 1698–705. (September 1999). doi:10.2337/diabetes.48.9.1698. PMID10480597.
“Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase”. Structure12 (3): 429–38. (March 2004). doi:10.1016/j.str.2004.02.005. PMID15016359. "Beautiful structural pictures illustrating the conformational changes and potential regulatory mechanisms"
“Transcriptional induction of glucokinase gene by insulin in cultured liver cells and its repression by the glucagon-cAMP system”. The Journal of Biological Chemistry264 (36): 21824–9. (December 1989). PMID2557341.
“Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut”. The Journal of Biological Chemistry269 (5): 3641–54. (February 1994). PMID8106409.
“Glucokinase (GCK) mutations in hyper- and hypoglycemia: maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemia of infancy”. Human Mutation22 (5): 353–62. (November 2003). doi:10.1002/humu.10277. PMID14517946.
“Glucokinase is an integral component of the insulin granules in glucose-responsive insulin secretory cells and does not translocate during glucose stimulation”. Diabetes53 (9): 2346–52. (September 2004). doi:10.2337/diabetes.53.9.2346. PMID15331544.
“Glucokinase activators in diabetes management”. Expert Opinion on Investigational Drugs17 (2): 145–67. (February 2008). doi:10.1517/13543784.17.2.145. PMID18230050.
“Assessing the potential of glucokinase activators in diabetes therapy”. Nature Reviews. Drug Discovery8 (5): 399–416. (May 2009). doi:10.1038/nrd2850. PMID19373249.
“A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014”. Expert Opinion on Therapeutic Patents24 (8): 875–91. (August 2014). doi:10.1517/13543776.2014.918957. PMID24821087.